Arax Advisory Partners’s Myriad Genetics MYGN Stock Holding History
Bought
Maintained
Sold
Other funds holding MYGN
VPC
Arax Advisory Partners's MYGN Position: Q2 2026 in Review
Arax Advisory Partners increased its Myriad Genetics (MYGN) stake by 3,552% in Q2 2026, buying an estimated $112K and bringing the position to 25,270 shares worth $144K. The position accounts for ﹤0.01% of the portfolio, ranked #2468.
Arax Advisory Partners first reported a position in MYGN in Q2 2024 and has held it in 7 quarters since. 196 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.
- Arax Advisory Partners held 25,270 shares of Myriad Genetics worth $144K as of Q2 2026.
- Arax Advisory Partners bought 24,578 Myriad Genetics shares in Q2 2026, an estimated $112K.
- Myriad Genetics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #2468 holding.
- Arax Advisory Partners first reported a position in Myriad Genetics in Q2 2024 and has held it in 7 quarters since.
- 196 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.
Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.